Astrana Health, Inc. (NASDAQ:ASTH) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Astrana Health, Inc. (NASDAQ:ASTH) have received a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $56.83.

ASTH has been the topic of several research reports. Bank of America cut their target price on Astrana Health from $55.00 to $49.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th. Truist Financial cut their price objective on Astrana Health from $59.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, January 13th. Macquarie raised Astrana Health to a “hold” rating in a research report on Monday, December 16th. Robert W. Baird cut their price objective on Astrana Health from $86.00 to $50.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Finally, Stifel Nicolaus cut their price objective on Astrana Health from $70.00 to $56.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th.

Astrana Health Trading Up 8.0 %

Shares of ASTH opened at $29.38 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $1.65 billion, a P/E ratio of 22.60, a price-to-earnings-growth ratio of 1.37 and a beta of 1.30. The stock’s fifty day simple moving average is $34.25 and its 200 day simple moving average is $43.80. Astrana Health has a twelve month low of $23.12 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last issued its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.22 by ($0.37). The firm had revenue of $665.21 million during the quarter, compared to analysts’ expectations of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. On average, equities research analysts forecast that Astrana Health will post 1.15 earnings per share for the current year.

Institutional Trading of Astrana Health

A number of hedge funds and other institutional investors have recently modified their holdings of ASTH. Louisiana State Employees Retirement System purchased a new stake in shares of Astrana Health during the third quarter worth about $1,165,000. State of Alaska Department of Revenue acquired a new position in Astrana Health in the third quarter worth about $1,373,000. Nisa Investment Advisors LLC acquired a new position in Astrana Health in the third quarter worth about $35,000. New York State Teachers Retirement System acquired a new position in Astrana Health in the third quarter worth about $2,515,000. Finally, F M Investments LLC acquired a new position in Astrana Health in the third quarter worth about $11,738,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.